Real-world use of mycophenolate mofetil in inflammatory bowel disease: Results from the ENEIDA registry.
Dig Liver Dis
; 54(5): 635-641, 2022 05.
Article
de En
| MEDLINE
| ID: mdl-34862115
ABSTRACT
BACKGROUND:
Studies to evaluate the use of mycophenolate mofetil (MMF) in inflammatory bowel disease (IBD) are limited after the appearance of biological treatments.AIMS:
Our primary objective was to evaluate the effectiveness and safety of MMF in IBD.METHODS:
IBD patients who had received MMF were retrieved from the ENEIDA registry. Clinical activity as per the Harvey-Bradshaw Index (HBI), partial Mayo score (pMS), physician global assessment (PGA) and C-reactive protein (CRP) were reviewed at baseline, at 3 and 6 months, and at final follow-up. Adverse events and causes of treatment discontinuation were documented.RESULTS:
A total of 83 patients were included (66 Crohn's disease, 17 ulcerative colitis), 90% of whom had previously received other immunosuppressants. In 61% of patients systemic steroids were used at initiation of MMF, and in 27.3% biological agents were co-administered with MMF. Overall clinical effectiveness was observed in 64.7% of the population. At the end of treatment, 45.6% and 19.1% of subjects showed remission and clinical response, respectively. MMF treatment was maintained for a median of 28.9 months (IQR 20.4-37.5).CONCLUSION:
Our study suggests, in the largest cohort to date, that MMF may be an effective alternative to thiopurines and methotrexate in IBD.Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Maladies inflammatoires intestinales
/
Rectocolite hémorragique
/
Maladie de Crohn
Limites:
Humans
Langue:
En
Journal:
Dig Liver Dis
Sujet du journal:
GASTROENTEROLOGIA
Année:
2022
Type de document:
Article